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Magnetic resonance guided radiotherapy (MRgRT) is the newest face of technology within
a field long-characterized by continual technologic advance. MRgRT may offer
improvement in the therapeutic index of radiation by offering novel planning types, like
online adaptation, and improved image guidance, but there is a paucity of randomized
data or ongoing randomized controlled trials (RCTs) to demonstrate clinical gains. Strong
clinical evidence is needed to confirm the theoretical advantages of MRgRT and for the
rapid dissemination of (and reimbursement for) appropriate use. Although some future
evidence for MRgRT may come from large registries and non-randomized studies, RCTs
should make up the core of this future data, and should be undertaken with thoughtful
preconception, endpoints that incorporate patient-reported outcomes, and warm
collaboration across existing MRgRT platforms. The advance and future success of
MRgRT hinges on collaborative pursuit of the RCT.
Keywords: MR-guided radiotherapy, RCT, evaluation, evidence, MRgRT
INTRODUCTION
Over the past several decades, the field of radiation oncology has witnessed a range of technical
innovations. We have seen paradigm-shifting advances in planning techniques, like intensity-
modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT). We have also
seen the introduction of particle therapy with protons and carbon ions, with the potential to better-
spare normal tissues, and improved precision of radiotherapy delivery with real-time tumor
tracking (1). We have witnessed the introduction and adoption of advanced image-guided
radiotherapy (IGRT) (2). Many, if not all of these innovations have (partly) replaced older
techniques, some with good evidence for benefit (3, 4). However, in some cases, this has been
without robust clinical evidence of superiority (5).
The newest of these technical advances to reach the mainstream clinic, magnetic resonance
guided radiotherapy (MRgRT), offers real-time near-diagnostic visualization of the tumor/patient
anatomy (6), enabling highly accurate online adaptive radiotherapy (ART), which by adjusting the
treatment plan based on the daily anatomy while the patient remains on the treatment table,
improves the dosimetric therapeutic index of radiation (7). This can be through both improved
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normal tissue sparing and/or accurate target dose escalation.
Online ART with MRgRT has the potential to improve patient
outcomes by reducing treatment-related toxicities and may
enable increased local disease control through safe dose
escalation. MRgRT also (presently) requires a more complex
and resource-intensive workflow (8–10), with greater overall cost
than standard RT.
The amount of clinical studies comparing MRgRT with CT
guided radiotherapy is limited, and the number of completed or
active randomized controlled trials (RCTs) even more so: in fact,
we were unable to identify RCTs comparing CT guided
radiotherapy with MRgRT, with the exception of one RCT in
prostate cancer (clinicaltrials.gov NCT04384770.
Despite absence of strong evidence of improved efficacy,
MRgRT is currently being implemented at many sites
worldwide (11). In this paper, we argue that patients and
societies can only truly benefit from this exciting new
technology when the MRgRT community collaborates to
generate solid clinical evidence, which, in large part, will
require large, comparative randomized studies.
ABSENCE OF STRONG CLINICAL
EVIDENCE IS BAD FOR PATIENTS
For many radiation oncologists, there is little doubt that MRgRT
will improve patient outcomes. They argue that it is only logical
that real-time target visualization, daily plan adaptation, and the
option to accurately pause treatment during organ/tumor
movement will lead to less irradiation of healthy tissue and
therefore less toxicity, or better tumor control. Some would even
say it is unethical to expose patients to less precise or accurate
treatment in the context of a comparative study or a randomized
controlled trial (RCT).
Yet, in medicine we have seen too many examples where the
theoretical benefits of new treatments were not confirmed in
clinical practice (12). There are also examples of promising new
interventions which turned out to be harmful for patients (13,
14), or beneficial in particular settings (15) but harmful in others
(16). This is even true in multiple examples where early Phase I
and II clinical evidence of seemingly obvious and stepwise
approaches suggested benefit (17), only to be proven wrong in
RCT (18). Indeed, despite the typically promising early phase
trial data that precedes an RCT, a shocking swath of Phase III
oncology trials are negative according to primary endpoint (19).
We should therefore pursue the highest possible level of evidence
for MRgRT, and with collaborative enthusiasm.
The argument that an RCT is unethical in the setting of
a “logically superior” technology also does not hold from
the perspective of reimbursement and patient access to care.
Although evidence is not the sole determinant of reimbursement
decisions, mainstream reimbursement for a new technology is
generally accelerated when high quality clinical evidence of
superiority becomes available (20, 21). Reimbursement patterns
in turn are related to access to particular types of care (22), as
well as to outcomes of patients with cancer, even with efforts to
control for comorbidities, stage, and similarly confounding
variables (23, 24). Therefore, the earlier we enter or (even
better) randomize some patients into control arms, the
sooner many more patients may benefit when superiority
is demonstrated.
Finally, from an economic perspective, it is also important to
conduct high quality, randomized research. MRgRT is more
expensive than most standard RT techniques, and like with any
new promising technology, not all patients will benefit from
MRgRT. There will be patients in whom the a priori risk of
toxicity is so limited, that there is simply very little room for
MRgRT to improve outcomes. Similarly, some patients will
experience high toxicity despite MRgRT. Thus, from a cost
perspective, we need to identify those patients and administer
MRgRT only to patients who are likely to benefit.
WHY WE NEED PROSPECTIVE TRIALS
AND RANDOMIZATION, AND NOT JUST
REAL-WORLD DATA
We need to demonstrate that theoretical benefits of MRgRT
translate into real benefits for patients. As of today, the RCT
remains the gold standard for demonstrating superiority of new
treatments. Some argue that ‘real world evidence’, coming from
large registries, can be a good alternative to RCTs. However,
evaluation of new treatments using real world data is prone to a
strong type of bias, i.e. confounding by indication. This type of
bias is prevented by randomization.
Confounding by indication occurs in daily practice, where
patients who are referred for a new, promising and innovative
treatment like MRgRT are different from patients who are not.
Usually, patients with access to innovative treatment are fitter,
have less comorbidity, are more educated, have healthier
lifestyles, and are better informed. Superior outcomes in these
patients cannot be solely attributed to the new treatment, as they
may very well be the result of difference in their pre-treatment
health status and prognosis. These factors are generally difficult
to measure and therefore impossible to (completely) adjust for by
statistical analysis. With randomization, the treatment choice is
based on chance only, and is independent of patient
characteristics. Confounding by indication cannot be prevented
in registry studies and real-world data, no matter how matter
how big or how detailed they are.
WHAT WORK NEEDS TO BE DONE
BEFORE WE CAN EMBARK ON RCTs
Before a new technology like MRgRT is ready for formal
comparison with the standard treatment, some preparatory steps
need to be taken. A possible framework for this has been proposed
is the R-IDEAL recommendations (25), based closely off of the
IDEAL recommendations (26). The R-IDEAL concept describes
the road towards evidence-based implementation of innovations
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in radiation oncology and starts with Stage 0 (Radiotherapy
predicate studies), followed by stage 1 (Idea, first in man) and
Stage 2a (technical development studies), after which clinical
effectiveness of the technology is evaluated in early randomized
controlled trials (Stage 2b, exploration, and Stage 3, assessment),
followed by long-term study (Stage 4) and surveillance.
One important step is to develop a method for proper patient
selection for trial entry. Not all patients are likely to benefit from
MRgRT: some may have good outcomes with standard
treatment, while in others the potential gain of MRgRT is so
small that it will not translate into clinically meaningful or
measurable improvements. An exceptionally elegant approach
for patient selection that comes from the field of proton therapy,
and may be readily applicable to MRgRT, is the model-based
indication (27). Model-based indication is a stepwise
methodology of selecting patients for a novel therapy when the
primary goal is to reduce treatment-related toxicity. This
approach comprises two phases, first to select patients who
may benefit from a novel technology (MRgRT for this
discussion) and second, to clinically validate MRgRT through
comparative studies, preferably RCTs. In the first phase, patient
selection is carried out by sequentially evaluating 1) normal
tissue complication probability (NTCP) estimates for tissues of
interest 2) in silico dosimetric comparison studies using MRgRT
and ART vs. standard IGRT and conventional planning 3) the
estimated clinical benefit based on the NTCP risk and potential
dosimetric gains (28). Then, in phase two, patients with an
expected clinical benefit (based on the phase one assessed
NTCP-value reduction) that meets a defined clinical threshold
will be enrolled in RCTs. Although this stepwise approach to
clinical trial development may seem unusually structured (and
perhaps aseptic), clinical development of MRgRT requires timely
identification of best applications to minimize resource waste
and to maximize the likelihood of long-term success.
Another area where pre-work is needed is the field of Health
Technology Assessment (HTA). With health care costs rising
disproportionally in many societies, payers and policy makers
are, understandably, not always overly enthusiastic to adopt or
reimburse new, more expensive interventions. Therefore, we
advocate for groups to perform early health technology
assessment, analyses where the costs per quality of life year
gained (QALYs) are calculated and compared between
technologies. In these models, assumptions of effectiveness and
costs are made, in order to identify areas where MRgRT has the
potential to become cost effective. These models will give insight,
for example, into what extent toxicity needs to be reduced in
order for MRgRT to become cost effective. Or, what the
maximum costs of MRgRT are allowed to be, given a certain
(likely) toxicity reduction. Conclusions of early HTA analyses
may have varying implications across different countries
worldwide, as the threshold for cost effectiveness varies
internationally. Through early identification of scenarios where
MRgRT will likely be too expensive or not incrementally effective
enough to be cost effective, with mindfulness of international
variation in cost-effectiveness, one can redirect research efforts to
more worthy tumor sites or treatment strategies.
WHAT ENDPOINTS DO WE NEED
TO CHOOSE?
Choice of endpoint will depend on the stage of development of
the technology. Of course, in early stages of technology and
clinical development, more advantageous dose distributions, and
lower dose to healthy tissues are encouraging and relevant.
Smaller margins, adaptive planning, and more favorable dose
distributions may indeed translate into lower toxicity of better
quality-of-life. Similarly, dose-escalated treatment plans with
sparing of organs-at-risk are likely to lead to better tumor
control. However, we strongly believe that, at some point
before widespread introduction of the technology, it is
important to demonstrate that these theoretical benefits,
confirmed by proxy endpoints, translate into real clinical
benefits for patients. In the era of shared decision making,
disease-free or progression-free survival are no longer the only
or most important outcomes of interest. Neither are doctor-
assessed acute and chronic toxicities.
We think that patients could, and should, play an important
role in relevant trial endpoints. Also, we believe that patients
themselves are in the best position to provide these endpoints.
There is no one better positioned to report outcomes in the
domains of physical functioning, role and social functioning, and
cognitive functioning than a patient themselves. Patient reported
outcomes (PROs) must be considered in MRgRT. Also, in terms
of “traditional” outcomes, like measured toxicity, instead of the
doctor taking a snap-shot at the outpatient clinic, we believe that
toxicity and functioning are better assessed by the patients
themselves at multiple time points during follow-up.
Fortunately, multiple technological solutions (including
established cloud-based solutions, apps, and websites) and
tools (such as the validated PRO-CTCAE, EORTC QLQ-C30,
and other questionnaires) are readily available (29–32). As
MRgRT study designs are considered, strong consideration
should be given to PRO-based endpoints as either primary or
complementary objectives.
DO WE ALWAYS NEED TO DO AN RCT?
As clear as our plea for the RCT in MRgRT may be, there are
clinical scenarios in which RCTs are impractical and
unnecessary. One such scenario is the evaluation of late effects.
It remains a challenge to establish high quality late toxicity data,
particularly when toxicities occur outside of standard clinical
trial windows. In this setting, large, high quality, multi-
institutional registries could play a pragmatic role in capturing
a diversity of potential events that could occur sporadically and
take place years following treatment completion. Given the
potential rarity, diversity, and variably long timeframe for late
toxicities to develop, they are an impractical endpoint for the
clinical development of a novel technology. We need evidence
for MRgRT imminently, and choices of late toxicities as primary
endpoints for initial RCTs in the field would unreasonably delay
clinical development. Similarly, RCTs for rare tumor sites where
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accrual is challenging and slow, remain impractical in the initial
development of MRgRT. Registries may again be useful in this
scenario. We would also argue that within particular body-site
settings, gains through technology advances like MRgRT are
often translatable across histologies. It stands to reason that if
MRgRT were proven beneficial in toxicity reduction of SBRT for
unresectable pancreatic cancer, it might similarly offer toxicity
reduction for SBRT to a renal cell carcinoma oligometastasis to
the pancreas.
Apart from late outcomes and rare cancers, it has also been
argued many times that RCTs are inappropriate for “parachute”
style situations. One would not perform an RCT of a parachute
use vs. jumping without.
Of course, there may be individual situations where the
anticipated benefit of MRGRT is too large to justify
randomization. However, in general, like most medical
practices, MRgRT is unlikely to present “parachute” style
scenarios (33). One does not need to look far into the history
of medicine to identify RCTs where the primary endpoints were
thought by many to be slam dunks, but were indeed ultimately
negative (34). Or, for that matter, where unexpected effects of
an experimental approach decimated any benefit (35). We
maintain that RCTs are the gold standard in oncology trials
and non-randomized and observational studies should not be
viewed as a replacement for them, but rather as a complement
to them in the pursuit of MRgRT development.
CAN VARYING MRGRT TREATMENT
PLATFORMS BE USED FOR A
COMMON GOAL?
In the clinical mainstream of MRgRT, two MR-linacs (MRL)
platforms are commercially available and in global use. They are
the 1.5-Tesla (T) MRL (Elekta Unity) and the 0.35T MRL
(Viewray MRIdian). Although the imaging units on board
these two MRLs vary in strength, the clinical imaging utility
itself is similar with regards to clinician ability to distinguish the
daily anatomy, even in complex soft tissue sites like the abdomen
(36). Indeed, we believe these systems are far more alike than
different, especially when placed in the context of other existing
linacs. We do recognize there may be particular niche
applications focused on imaging endpoints that may be best
performed on one platform vs the other for consistency (37).
However, the broad capabilities of the MRL systems, like online
adaptation (whether it is referred to as “SMART” or “adapt to
shape”) or MR-guided alignment and gating (MR-based setup,
whether given the name “adapt to position” or not) are mainly
translatable across platforms, with no greater difference than that
between an Elekta Versa and a Varian Truebeam (the modern,
high-throughput CT-based linacs at time of this writing). There
is indeed long-standing precedent in the field of radiation
oncology to permit multiple disparate technologies within a
single trial, even with different imaging types, different multi-leaf
collimators, and different motion management, as long as the
delivered therapy is overall equivalent. To say that the 1.5T and
0.35T systems cannot be used interchangeably in a trial of online
adaptation would be like saying a lung SBRT trial could only occur
on a Truebeam, but not a tomotherapy or Cyberknife unit (38).
Focusing on differences between MRLs, rather than similarities,
will only divide efforts, attention, funding, and patient resources,
and ultimately delay the success of MRgRT. Thus, RCT and other
study efforts should aim to be collaborative across platforms and
institutions, to maximize the timely impact of this new technology.
Both platforms have formed consortia, where radiation
oncologists, physicists, methodologists and other experts
collaborate to work towards evidence-based implementation of
the technology and optimized radiation treatment approaches to
improve patients’ outcomes (39). These consortia are in the
excellent position to design and initiate international, platform
agnostic, multicenter RCTs.
Finally, it will be challenging to find the right balance
between having enough sites offering MRgRT to run RCTs,
while avoiding large scale uptake of the technology withouth
clinical evidence. As with many technical innovations, the time
window for RCTs is narrow. We should avoid a situation
where MRgRT has been implemented on a large scale, where
radiation oncologists and therapists have become accustomed
to providing MRgRT, and where it has become too late to
de-implement the technology for tumor sites of patient
categories where RCTs have not been able to confirm
superiority or cost-effectiveness. Therefor, it is imperative to
start RCTs sooner rather than later.
CONCLUSION
We believe that RCTs are central to the future success of MRgRT.
Randomized data will help to identify and substantiate the
potential clinical gains of MR-guidance, and will ensure
coordinated dissemination of this novel technology. The
MRgRT community needs to unite across platforms to enable
thoughtful conception of randomized trials, with modern
endpoints, and with timely generation of the high-quality
evidence needed to support the future of the field.
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